Drug Profile

ALN AAT02

Alternative Names: ALN-AAT02

Latest Information Update: 29 Dec 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Alnylam Pharmaceuticals
Class Hepatoprotectants; Small interfering RNA
Mechanism of Action Alpha 1-antitrypsin inhibitors; RNA interference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I/II Alpha 1-antitrypsin deficiency

Most Recent Events

28 Dec 2021 Dicerna Pharmaceuticals has been acquired by Novo Nordisk
17 Sep 2020 Alnylam Pharmaceuticals terminated a phase I/II trial for Apha-1 antitrypsin deficiency in United Kingdom due to business reasons (NCT03767829) (EudraCT2018-001362-41)
06 Apr 2020 Alnylam Pharmaceuticals collaborates with Dicerna Pharmaceuticals for Alpha-1 antitrypsin deficiency-associated liver disease

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com